migraines Word Scramble
A B S C E E N
|
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
| Question | Answer |
| clinical uses of valproic acid | generalized seizures, absence seizures, migraine prophylaxis |
| post partum hemorrhage | ergot alkaloids |
| NSAIDS most effective when | taken early on in an attack |
| helps w/nausea/vomitting in migraines | metoclopramide |
| LSD | ergot alkaloid |
| MOA of amitriptyline, dothiepin, & nortriptyline | 5HT & NE reuptake inhibitors, block Na+ channels, |
| contraindications of triptans | CV disease and cerebrovascular disease |
| not effective in migraines w/aura until after the headache has already begun | triptans |
| contraindications for metclopramide | pheochromocytoma, PD |
| analgesic, anti-pyretic, and sedative drug | dichloralphenazone |
| potent vasoconstrictor | isometheptene |
| MOA of meteoclopramide | 5HT4 agonist, D2 antagonist, 5HT3 antagonist |
| NSAIDS most effective when | taken early on in an attack |
| side effects of ergot alkaloids | leg weakness, muscle pain, numbness/tingling, GI issues, nausea |
| triptans & ergot alkaloids are.. 5HT agonists | |
| bromocriptine | ergot alkaloid |
| 3 major components of theory of cortical spreading depression | correlates to visual field distrubances, mediated by release of pro-inflam neuropeptides, involves activating of trigeminal afferents from dural vasculature |
| drugs for acute migraines | triptans, ergot alkaloids, DA antagonists, narcotics, combination |
| sumatriptan | 5HT1 agonist |
| may be associated with withdrawl sx | gabapentin |
| MOA ofgabapentin | inhibits ca++ channels |
| 3 major arguments for serotonin theory | anti-migraine agents are 5HT agonists/antagonists, increased risk of attack during resperpine/fenfluramine therapy |
| receptors affected by chlorpromazine & prochlorperazine | DA, Ach, adrenergic, histaminergic |
| administration of meperidine | IV |
| 5HT1 agonists + DA antagonists used for | severe acute attacks |
| MOA of triptans | vasoconstriction & 5HT-1 mediated inhibition of CGRP |
| DA antagonists used to treat migraines chlorpromazine & prochlorperazine | |
| 1 dose of sumatriptan = | aspirin + metoclopramide |
| contraindications of egot alkaloids | pregnancy, PAD, CAD, HTN, impaired renal/hepatic function |
| clinical uses of tricyclics | migraine prophylaxis, pain syn, chronic fatigue syn |
| amidrine = | acetaminophen + dichloralphenazone + isometheptene |
| side effect of pizotifen | weight gain, drowsiness, anti-muscarinic effect |
| propanolol use | prophylactic drug for migraines |
| most effecacious triptans | rizatriptan,eletriptan; sumatriptan, zolmitriptan |
| pizotifen use | prophylactic drug for migraines |
| clinical uses of methysergide | migraine prophylaxis, severe refractory migraines, cluster headaches |
| benefit of nasal spray 5HT1 agonists | faster and more effective relief |
| clinical uses of chlorpromazine & prochlorpromazine | antiemetic, schizophrenia, tourette syn, huntington disease, dementia |
| extremely potent vasodilator neuropeptide | calcitonin gene related peptide |
| 5HT1 agonists + DA antagonists used for | severe acute attacks |
| pizotifen use | prophylactic drug for migraines |
| adverse effects of DA antagonists | poikilothermic, blurred vision, constipation, agranulocytosis, phototoxicity, EPS |
| administration of butorphanol | intranasal spray |
| migraine prophylaxis drugs | propranolol, pizotifen, tricyclic Ads, valproic acid, gabapentin, methysergide |
| butorphanol | narcotic |
| potent vasoconstrictor | isometheptene |
| propanolol use | prophylactic drug for migraines |
| MOA of pizotifen | 5HT1, 2A, & 2C antagonist, with some anti-histamine/cholinergic effects |
| benefit of nasal spray 5HT1 agonists | faster and more effective relief |
| side effect of pizotifen | weight gain, drowsiness, anti-muscarinic effect |
| adverse effects of DA antagonists | poikilothermic, blurred vision, constipation, agranulocytosis, phototoxicity, EPS |
| concern for addiction liability | oxycodone, hydrocodone, etc |
| 1 dose of sumatriptan = | aspirin + metoclopramide |
| analgesic, anti-pyretic, and sedative drug | dichloralphenazone |
| MOA of valproid acid | prolongs inactive state of Na+ channels, inhibits Ca++ channels, increases GABA |
| methysergide | ergot alkaloid |
| receptors affected by chlorpromazine & prochlorperazine | DA, Ach, adrenergic, histaminergic |
| retroperitoneal fibrosis | methysergide |
| MOA of methysergide | 5HT2 & 5HT1A antagonist |
| least efficacious triptans | naratriptan, frovatriptan |
| meperidine | narcotic |
| MOA of butorphanol | partial agonist @u, full agonist @k |
| agonists at 5HT and a1 receptors | ergot alkaloids |
| zolmitriptan | 5HT1 agonist |
| may precipitate mania in bipolar pts | tricyclic antidepressants |
| metoclopramide | DA antagonists |
| adverse effects of metoclopramide | galactorrhea, constipation, EPS, tardive dyskinesia |
| receptors acted on by ergot alkaloids | 5HT1 |
| dihydroergotamine | 5HT1 agonist |
| MOA of pizotifen | 5HT1, 2A, & 2C antagonist, with some anti-histamine/cholinergic effects |
| receptors acted on by triptans | 5HT 1B & 1D |
| acetaminophen + dichloralphenazone + isometheptene = | amidrine |
| amidrine = | acetaminophen + dichloralphenazone + isometheptene |
Created by:
drhermy